Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: A review of the science, the clinical data, and patient satisfaction

Koenraad De Boulle1, Steven Fagien2, Boris Sommer3, Richard Glogau41Aalst Dermatology Clinic, Aalst, Belgium; 2Aesthetic Eyelid Plastic, Surgery, Boca Raton, FL, USA; 3Aesthetic Dermatology, Frankfurt, Germany; 4University of California, San Francisco, USAAbstract: Botulinum toxin type A treatment i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Koenraad De Boulle, Steven Fagien, Boris Sommer, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	onabotulinumtoxinA botulinum toxin type A cosmetic glabellar patient satisfaction Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/fcc4db8fad754b8ab2f50a547caf1491
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fcc4db8fad754b8ab2f50a547caf1491
record_format	dspace
spelling	oai:doaj.org-article:fcc4db8fad754b8ab2f50a547caf14912021-12-02T01:40:21ZTreating glabellar lines with botulinum toxin type A-hemagglutinin complex: A review of the science, the clinical data, and patient satisfaction1178-1998https://doaj.org/article/fcc4db8fad754b8ab2f50a547caf14912010-04-01T00:00:00Zhttps://www.dovepress.com/treating-glabellar-lines-with-botulinum-toxin-type-a-hemagglutinin-com-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Koenraad De Boulle1, Steven Fagien2, Boris Sommer3, Richard Glogau41Aalst Dermatology Clinic, Aalst, Belgium; 2Aesthetic Eyelid Plastic, Surgery, Boca Raton, FL, USA; 3Aesthetic Dermatology, Frankfurt, Germany; 4University of California, San Francisco, USAAbstract: Botulinum toxin type A treatment is the foundation of minimally invasive aesthetic facial procedures. Clinicians and their patients recognize the important role, both negative and positive, that facial expression, particularly the glabellar frown lines, plays in self-perception, emotional well-being, and perception by others. This article provides up-to-date information on fundamental properties and mechanisms of action of the major approved formulations of botulinum toxin type A, summarizes recent changes in naming conventions (nonproprietary names) mandated by the United States Food and Drug Administration, and describes the reasons for these changes. The request for these changes provides recognition that formulations of botulinum toxins (eg, onabotulinumtoxinA and abobotulinumtoxinA) are not interchangeable and that dosing recommendations cannot be based on any one single conversion ratio. The extensive safety, tolerability, and efficacy data are summarized in detail, including the patient-reported outcomes that contribute to overall patient satisfaction and probability treatment continuation. Based on this in-depth review, the authors conclude that botulinum toxin type A treatment remains a cornerstone of facial aesthetic treatments, and clinicians must realize that techniques and dosing from one formulation cannot be applied to others, that each patient should undergo a full aesthetic evaluation, and that products and procedures must be selected in the context of individual needs and goals.Keywords: onabotulinumtoxinA, botulinum toxin type A, cosmetic, glabellar, patient satisfactionKoenraad De BoulleSteven FagienBoris Sommeret alDove Medical PressarticleonabotulinumtoxinAbotulinum toxin type Acosmeticglabellarpatient satisfactionGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 5, Pp 101-118 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	onabotulinumtoxinA botulinum toxin type A cosmetic glabellar patient satisfaction Geriatrics RC952-954.6
spellingShingle	onabotulinumtoxinA botulinum toxin type A cosmetic glabellar patient satisfaction Geriatrics RC952-954.6 Koenraad De Boulle Steven Fagien Boris Sommer et al Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: A review of the science, the clinical data, and patient satisfaction
description	Koenraad De Boulle1, Steven Fagien2, Boris Sommer3, Richard Glogau41Aalst Dermatology Clinic, Aalst, Belgium; 2Aesthetic Eyelid Plastic, Surgery, Boca Raton, FL, USA; 3Aesthetic Dermatology, Frankfurt, Germany; 4University of California, San Francisco, USAAbstract: Botulinum toxin type A treatment is the foundation of minimally invasive aesthetic facial procedures. Clinicians and their patients recognize the important role, both negative and positive, that facial expression, particularly the glabellar frown lines, plays in self-perception, emotional well-being, and perception by others. This article provides up-to-date information on fundamental properties and mechanisms of action of the major approved formulations of botulinum toxin type A, summarizes recent changes in naming conventions (nonproprietary names) mandated by the United States Food and Drug Administration, and describes the reasons for these changes. The request for these changes provides recognition that formulations of botulinum toxins (eg, onabotulinumtoxinA and abobotulinumtoxinA) are not interchangeable and that dosing recommendations cannot be based on any one single conversion ratio. The extensive safety, tolerability, and efficacy data are summarized in detail, including the patient-reported outcomes that contribute to overall patient satisfaction and probability treatment continuation. Based on this in-depth review, the authors conclude that botulinum toxin type A treatment remains a cornerstone of facial aesthetic treatments, and clinicians must realize that techniques and dosing from one formulation cannot be applied to others, that each patient should undergo a full aesthetic evaluation, and that products and procedures must be selected in the context of individual needs and goals.Keywords: onabotulinumtoxinA, botulinum toxin type A, cosmetic, glabellar, patient satisfaction
format	article
author	Koenraad De Boulle Steven Fagien Boris Sommer et al
author_facet	Koenraad De Boulle Steven Fagien Boris Sommer et al
author_sort	Koenraad De Boulle
title	Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: A review of the science, the clinical data, and patient satisfaction
title_short	Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: A review of the science, the clinical data, and patient satisfaction
title_full	Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: A review of the science, the clinical data, and patient satisfaction
title_fullStr	Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: A review of the science, the clinical data, and patient satisfaction
title_full_unstemmed	Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: A review of the science, the clinical data, and patient satisfaction
title_sort	treating glabellar lines with botulinum toxin type a-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/fcc4db8fad754b8ab2f50a547caf1491
work_keys_str_mv	AT koenraaddeboulle treatingglabellarlineswithbotulinumtoxintypeahemagglutinincomplexareviewofthesciencetheclinicaldataandpatientsatisfaction AT stevenfagien treatingglabellarlineswithbotulinumtoxintypeahemagglutinincomplexareviewofthesciencetheclinicaldataandpatientsatisfaction AT borissommer treatingglabellarlineswithbotulinumtoxintypeahemagglutinincomplexareviewofthesciencetheclinicaldataandpatientsatisfaction AT etal treatingglabellarlineswithbotulinumtoxintypeahemagglutinincomplexareviewofthesciencetheclinicaldataandpatientsatisfaction
_version_	1718402994588876800

Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: A review of the science, the clinical data, and patient satisfaction

Ejemplares similares